Karyopharm Therapeutics Inc. (KPTI) Earns “Outperform” Rating from Leerink Swann
Karyopharm Therapeutics Inc. (NASDAQ:KPTI)‘s stock had its “outperform” rating reissued by equities research analysts at Leerink Swann in a research note issued on Friday. They presently have a $18.00 price objective on the stock. Leerink Swann’s price objective indicates a potential upside of 88.28% from the stock’s current price.
KPTI has been the topic of a number of other research reports. Canaccord Genuity set a $20.00 price objective on shares of Karyopharm Therapeutics and gave the stock a “buy” rating in a research note on Saturday, August 6th. Zacks Investment Research cut shares of Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, July 12th. HC Wainwright began coverage on shares of Karyopharm Therapeutics in a research note on Thursday, August 18th. They set a “buy” rating and a $15.00 price objective on the stock. Robert W. Baird began coverage on shares of Karyopharm Therapeutics in a research note on Monday, June 27th. They set an “outperform” rating and a $16.00 price objective on the stock. Finally, Wedbush reaffirmed an “outperform” rating and set a $14.00 price objective on shares of Karyopharm Therapeutics in a research note on Friday, June 10th. Two research analysts have rated the stock with a sell rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. Karyopharm Therapeutics has an average rating of “Buy” and a consensus price target of $16.04.
Shares of Karyopharm Therapeutics (NASDAQ:KPTI) traded down 1.54% during midday trading on Friday, reaching $9.56. 166,190 shares of the company traded hands. Karyopharm Therapeutics has a 1-year low of $4.83 and a 1-year high of $19.41. The firm’s market capitalization is $344.05 million. The stock has a 50 day moving average price of $9.04 and a 200 day moving average price of $8.40.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/07/karyopharm-therapeutics-inc-kpti-earns-outperform-rating-from-leerink-swann.html
Karyopharm Therapeutics (NASDAQ:KPTI) last issued its quarterly earnings results on Thursday, August 4th. The company reported ($0.84) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.76) by $0.08. Analysts expect that Karyopharm Therapeutics will post ($3.22) earnings per share for the current fiscal year.
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Schwab Charles Investment Management Inc. raised its position in shares of Karyopharm Therapeutics by 1.5% in the second quarter. Schwab Charles Investment Management Inc. now owns 60,498 shares of the company’s stock worth $406,000 after buying an additional 882 shares during the last quarter. Palo Alto Investors LLC raised its position in shares of Karyopharm Therapeutics by 1.3% in the second quarter. Palo Alto Investors LLC now owns 3,139,433 shares of the company’s stock worth $21,066,000 after buying an additional 41,288 shares during the last quarter. Metropolitan Life Insurance Co. NY purchased a new position in shares of Karyopharm Therapeutics during the second quarter worth $136,000. Highbridge Capital Management LLC purchased a new position in shares of Karyopharm Therapeutics during the second quarter worth $200,000. Finally, New Leaf Venture Partners L.L.C. raised its position in shares of Karyopharm Therapeutics by 1,723.5% in the second quarter. New Leaf Venture Partners L.L.C. now owns 222,947 shares of the company’s stock worth $1,496,000 after buying an additional 210,721 shares during the last quarter. Institutional investors own 55.71% of the company’s stock.
Karyopharm Therapeutics Company Profile
Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its segment is the business of discovering, developing and commercializing drugs to treat cancer and certain other major diseases.
Receive News & Ratings for Karyopharm Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.